Evidence map›Paper›PMID 42445199›Full record

ReviewFrontiers in immunology2026

Multiple sclerosis as an asynchronous neuroinflammatory system.

Emanuele D'Amico, Aurora Zanghì, Daniel Ontaneda

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Emanuele D'Amico *Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Aurora Zanghì *Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Daniel OntanedaMellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) has traditionally been conceptualized through an event-based framework in which relapses, lesion accumulation, and disability progression evolve along a linear temporal axis. However, converging pathological, imaging, biomarker, and clinical trial evidence indicates that inflammatory activity, chronic lesion expansion, axonal degeneration, and network reorganization unfold with partially independent temporal dynamics. The 2024 revisions of the McDonald criteria formally incorporate markers of immune persistence and chronic inflammatory organization. Dissemination in space (DIS) remains the diagnostic entry point with a relaxation for the need of dissemination in time (DIT) yet prognosis cannot be reduced to event frequency alone. Disability accumulation reflects the interaction between Relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA), revealing a decomposable hazard structure that challenges relapse-centered modeling. Traditional endpoints such as annualized relapse rate (ARR) and confirmed disability progression (CDP) capture partial projections of a higher-dimensional disease process. MS should therefore be understood not as an event-driven disorder but as a dynamically evolving system. Biological onset occurs before clinical presentation, diagnosis occurs at a threshold; progression unfolds as a trajectory through a multidimensional state space (MSS). Recognizing this distinction has direct implications for prognostic inference, trial design, biomarker integration, and state-dependent therapeutic modeling.

Indexed as

Multiple SclerosisNeuroinflammatory DiseasesAnimalsBiomarkersDisease ProgressionHumansPrognosisBiomarkersasynchronous dynamicsclinical trial modelingdisease progressionmultidimensional state spacemultiple sclerosis

Identifiers

PMID42445199
PMCPMC13357223

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.